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Soluble amyloid- (A) peptide is likely to play a key role during early stages of Alzheimer’s disease (AD) by perturbing synaptic function
and cognitive processes. Receptor for advanced glycation end products (RAGE) has been identified as a receptor involved in A-induced
neuronal dysfunction. We investigated the role of neuronal RAGE in A-induced synaptic dysfunction in the entorhinal cortex, an area
of the brain important in memory processes that is affected early in AD. We found that soluble oligomeric A peptide (A42) blocked
long-term potentiation (LTP), but did not affect long-term depression, paired-pulse facilitation, or basal synaptic transmission. In
contrast, A did not inhibit LTP in slices from RAGE-null mutant mice or in slices from wild-type mice treated with anti-RAGE IgG.
Similarly, transgenic mice expressing a dominant-negative form of RAGE targeted to neurons showed normal LTP in the presence of A,
suggesting that neuronal RAGE functions as a signal transducer for A-mediated LTP impairment. To investigate intracellular pathway
transducing RAGE activation by A, we used inhibitors of stress activated kinases. We found that inhibiting p38 mitogen-activated
protein kinase (p38 MAPK), but not blocking c-Jun N-terminal kinase activation, was capable of maintaining LTP in A-treated slices.
Moreover, A-mediated enhancement of p38 MAPK phosphorylation in cortical neurons was reduced by blocking antibodies to RAGE.
Together, our results indicate that A impairs LTP in the entorhinal cortex through neuronal RAGE-mediated activation of p38 MAPK.
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Introduction
Overproduction and accumulation of amyloid- (A) is a patho-
logic feature of Alzheimer’s disease (AD). A, particularly A42,
has been ascribed a crucial role in neuronal stress (Eisenhauer et
al., 2000; Johnson et al., 2002). Studies in AD animal models have
highlighted a dichotomy between behavioral deficits and neuro-
pathologic findings. Impaired memory and synaptic loss occur
before extensive deposition of amyloid in the brains of AD-type
murine models and AD patients (D’Hooge et al., 1996; Hsia et al.,
1999; Li et al., 1999; Chapman et al., 1999; Larson et al., 1999;
Giacchino et al., 2000; Wirths et al., 2001; Oddo et al., 2003;
Ingelsson et al., 2004). These observations suggest that early in
AD, when levels of A are low, mechanisms amplifying and fo-
cusing the effects of A on cellular targets contribute to neuronal
dysfunction.
Previous studies showed that A affects synaptic plasticity in
the hippocampus (for a review, see Selkoe, 2002). In particular,
oligomeric A42 was capable of acutely inhibiting long-term po-
tentiation (LTP) (Lambert et al., 1998; Chen et al., 2002; Walsh et
al., 2002, 2005; Wang et al., 2004; Zhao et al., 2004), one form of
synaptic plasticity that is thought to underlie learning and mem-
ory (Whitlock et al., 2006). Remarkably, LTP in the hippocampus
was inhibited by naturally secreted human A oligomers when
administered in the nanomolar range (Walsh et al., 2002; Wang et
al., 2004). Previously, a few reports showed that administration of
A at low micromolar concentrations depressed synaptic trans-
mission by interacting with glutamate receptors (Snyder et al.,
2005; Tyszkiewicz and Yan, 2005; Hsieh et al., 2006; Paramesh-
waran et al., 2007). Together, these results indicate the relevance
of identifying cell surface acceptor sites mediating the interaction
with oligomeric A and, as a consequence, activating signal
transduction mechanisms contributing to synaptic dysfunction.
The receptor for advanced glycation end products (RAGE), a
Received June 15, 2007; revised Feb. 19, 2008; accepted Feb. 22, 2008.
This work was supported by National Institutes of Health Grant PO1AG17490 and the Alzheimer’s Association
(S.D.Y.), and Fondazione Cassa di Risparmio di Pisa (05/140) and Italian Ministero Università e Ricerca (PRIN, 2006)
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multiligand receptor in the Ig superfamily, functions as a cell
surface binding site for A (Yan et al., 1996). Experimental evi-
dence has shown that RAGE is a receptor that directs the effects of
A to target cells (neurons, glia, endothelial cells) (Yan et al.,
1995; Hofmann et al., 1999; Lue et al., 2001; Schmidt et al., 2001;
Deane et al., 2003; Lue et al., 2005). Furthermore, introduction of
a wild-type (WT) RAGE transgene in neurons in the AD-type
transgenic (Tg) mouse model expressing mutant human amyloid
precursor protein (mAPP) accelerated A-mediated neuronal
perturbation (Arancio et al., 2004).
In the present work, we investigated the effect of oligomeric
A42 at a concentration of 200 nM on LTP, long-term depression
(LTD), paired-pulse facilitation, and basal synaptic transmission
in entorhinal cortex, an area affected at an early stage of AD
(Braak and Braak, 1991). In addition, we investigated the role of
RAGE and signal transduction pathways, p38 and c-Jun
N-terminal kinase (JNK) mitogen-activated protein kinases
(MAPKs) in A-induced synaptic dysfunction. Finally, we have
used a cell culture model to investigate RAGE-triggered signal
transduction mechanisms underlying the effects of pathophysi-
ologically relevant concentrations of A (200 nM), focusing on
these key intracellular kinases.
Materials and Methods
Homozygous RAGE-null and transgenic DN-RAGE mice. Homozygous
RAGE-null mice were generated and characterized as described previ-
ously (Sakaguchi et al., 2003; Wendt et al., 2003). Homozygous RAGE-
null mice were backcrossed for 10 generations into the C57BL/6 back-
ground. In addition we used transgenic mice with signal transduction
deficient mutants of RAGE in which the cytosolic domain of the receptor
has been deleted, thereby imparting a dominant-negative (DN)-RAGE
effect, targeted to neurons (DN-RAGE) driven by the platelet-derived
growth factor-B (PDGF-B) chain promoter. The PDGF-B chain pro-
moter has been successfully used to drive expression of transgene tar-
geted to neurons (Sasahara et al., 1991; Mucke et al., 2000; Lustbader et
al., 2004; Takuma et al., 2005). Furthermore, transgenic mice expressing
neuronal DN-RAGE driven by the PDGF-B chain promoter have been
previously characterized, demonstrating localization of DN-RAGE in
cortical neurons (Arancio et al., 2004). Male RAGE-null, male transgenic
DN-RAGE and littermate control mice were used for in vitro electrophys-
iology (age range, 2–3 months) (see below, Slice preparation).
Pharmacologic agents. A42 and the reversed peptide A(42–1) were
purchased from Biosource (Camarillo, CA). Oligomeric A42 peptide
was prepared as described previously, and characterized by atomic force
microscopy (Yan et al., 2007) and mass spectrometry (Voyager DE PRO
MALDI; Applied Biosystems, Warrington, UK). Aliquots were stored at
20°C in DMSO as a 200 M stock solution and diluted to the desired
final concentration in artificial CSF [ACSF; containing (in mM) 119
NaCl, 2.5 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 26.2 NaHCO3, 11 glu-
cose], immediately before application (Simmons et al., 1994). 4-(4-
Fluorophenyl)-2-(4-metylsulfinylphenyl)-5-(4-pyridyl)-1 H-imidazole
(SB203580) and anthra(1–9-cd) pyrazol-6(2 H)-one (SP600125) were
purchased from Alexis (Grünberg, Germany) and prepared in DMSO
stock solutions. These drugs were also diluted to the desired final con-
centration in ACSF. Specific antibodies to RAGE have been described in
our previous studies (Yan et al., 1996) and purified rabbit IgG was used as
a control (Bethyl, Montgomery, TX).
Slice preparation. RAGE-null mice, transgenic DN-RAGE mice, and
littermate control mice (age range, 2–3 months) were used. Animals were
deeply anesthetized using urethane (20% solution, 0.1 ml/100 g body
weight) via intraperitoneal injection and then decapitated after disap-
pearance of the tail pinch reflex. The brain was rapidly removed and thick
horizontal sections (400 m) containing the entorhinal area were made
on a Vibratome. All steps were performed in ice-cold ACSF solution
bubbled with 95% O2/5% CO2. Before recording, slices were stored for at
least 1 h in a recovery chamber containing oxygenated ACSF solution at
room temperature. During electrophysiological recordings, slices were
perfused at a rate of 2.5–3 ml/min with oxygenated ACSF at 33  1°C.
Electrophysiological recordings. Extracellular field potentials (FPs) were
evoked in layer III in response to electrical stimulation of layer II (see Fig.
1 A, schematic diagram). The amplitude of the FPs was used as a measure
of the evoked population excitatory current (Domenici et al., 1995; Pe-
savento et al., 2002). All FPs had peak latency between 4.5 and 6 ms.
Amplitudes of FPs were calculated at different stimulus intensities to
obtain input– output curves. Experiments to assess paired-pulse stimu-
lation (PP) were performed as well; two consecutive stimuli were applied
at different interstimulus intervals (30 –200 ms). PP-induced change was
calculated as the ratio of the peak amplitude of the second FP to the first
one. Baseline responses were obtained with a stimulation intensity that
yielded 50 – 60% of maximal amplitude. FP amplitude was monitored
every 20 s and averaged every three responses by online data acquisition
software (Anderson and Collingridge, 2001). After 15 min of stable base-
line recording, high-frequency stimulation (HFS; three trains of 100
pulses at 100 Hz, 10 s interval) or low-frequency stimulation (LFS; 900
paired pulses at 1Hz, the interval between paired pulses was 30 ms)
(Kourrich and Chapman, 2003) was used to induce LTP or LTD, respec-
tively. LTP and LTD magnitude were measured as the average of FP
amplitudes between the 40th and the 50th min after termination of in-
duction protocol. Values were expressed as mean  SEM percentage
change relative to their mean baseline amplitude. A peptides were ap-
plied by general perfusion for 10 min starting 5 min before HFS and LFS.
In experiments using the P38 MAPK inhibitor (SB203580) or JNK inhib-
itor (SP600125), compounds were continuously perfused over slices
starting at least 30 min before HFS or LFS.
Cell culture experiments. Primary cell cultures were prepared as fol-
lows: cortex from 0- to 3-d-old mice was dissected. Dissections were
performed in 200 M kynurenic acid (Sigma, St. Louis, MO) and 25 M
2-amino-5-phosphonovalerate (Tocris Cookson, Bristol, UK) on ice.
Tissue slices were digested with trypsin in the presence of DNAase,
blocked with a trypsin inhibitor on ice, and dissociated in medium con-
taining DNAase. Cells were recovered, washed by two successive centrif-
ugations, and plated on glass coverslips coated with 50 g/ml polyorni-
thine and 2% Matrigel (Collaborative Research, Bedford, MA) in 35 mm
Nunc (Naperville, IL) Petri dishes. Cells were maintained for 7–10 d in a
5% CO2 humidified incubator at 37°C, in minimum essential medium
with Earle’s salts and Glutamax I (Invitrogen, Carlsbad, CA) to which
5–10% fetal bovine serum, 6 mg/ml D-glucose, 3.6 mg/ml HEPES, 0.1
g/ml biotin, 1.5 g/ml vitamin B12, 30 g/ml insulin, and 100 g/ml
bovine transferrin (Sigma) were added. Proliferation of non-neuronal
cells was prevented by the addition of 2.5–5.0 M cytosine -D-
arabinofuranoside (Sigma) from the second day in culture. To assess
viability, cells were incubated with Hoechst 33342 (0.3 ng/ml) and pro-
pidium iodide (PI) (1 g/ml) in culture medium for 1 h in a CO2 incu-
bator at 37°C, washed in PBS and mounted on microscope slides; double
staining was analyzed with a fluorescence microscope (BC 1083 INV
11722; Nikon, Tokyo, Japan). PI is a polar compound which only enters
damaged cell membranes; inside cells, it binds to nucleic acids and be-
comes brightly red fluorescent. In a separate set of experiments, cell
viability was assayed using CytoTox 96 Non-Radioactive Cytotoxicity
Assay kit (Promega, Madison, WI) according to the manufacturer’s pro-
tocol. This assay measures lactate dehydrogenase (LDH) activity through
the conversion of a tetrazolium salt into a red formazan product. Relative
absorbance was measured at 490 nm using a microplate reader (Bio-Rad,
Hercules, CA). Background LDH release, determined in nontreated/con-
trol cultures, was subtracted from all experimental values. Finally, we
used an antibody recognizing the active form of Caspase-3 (Promega), as
a marker of apoptosis, followed by a secondary anti-rabbit antibody
conjugated with Alexa Fluor 488. Apoptotic neurons appeared as green
fluorescent cells.
ELISA assay. Quantification of phosphorylated [pTpY180/182] and
total p38 MAPK was detected in protein extracts from neuronal cell
cultures using two different ELISA kits (Biosource, Camarillo, CA) ac-
cording to the manufacturer’s protocol. Cell pellets were collected, im-
mediately frozen at 80°C, and subsequently lysed in cell extraction
buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1
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mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glyc-
erol, 0.1% SDS, 0.5% deoxycholate, and 1 mM PMSF; Sigma protease
mixture inhibitor). The extract was then centrifuged (13,000 rpm, 10
min at 4°C) to obtain a clear lysate that was used for the assay. Samples
were pipetted into wells coated with a specific monoclonal antibody
against p38 MAPK (regardless of phosphorylation state); after washing,
the detection antibody (rabbit anti-p38 MAPK [pTpY180/182] or rabbit
anti-total-p38 MAPK) was added to wells. The sandwich was completed
by adding anti-rabbit IgG-HRP conjugated. After completing the reac-
tion with stabilized chromogen (tetramethylbenzidine), absorbance was
read at 450 nm using a microplate reader (Bio-Rad). Values are expressed
as p38 MAPK [pTpY180/182] units normalized for the content of total
p38 MAPK.
Statistical analysis. Statistical comparisons between experimental
groups or between FP amplitudes measured
during baseline and after the induction proto-
col were performed by applying a two-way
repeated-measures ANOVA with pairwise
multiple comparison procedures (Holm–Sidak
method). Comparisons between different
groups in cell culture experiments were per-
formed using one-way ANOVA. Differences
were considered significant when p  0.05.
Results
Application of oligomeric A42 affects
LTP in the entorhinal cortex
We focused our studies on the entorhinal
cortex, an area of the brain crucially in-
volved in cognitive and memory processes
that is reciprocally connected to the hip-
pocampus and associative cortical areas.
In particular, the distribution of its affer-
ent, efferent, and associational projections
suggests that different rostrocaudal strips
of entorhinal cortex may operate indepen-
dently in processing neocortex- and
hippocampus-originated information
(Witter et al., 1989; Dolorfo and Amaral,
1998). We recorded FPs in horizontal sec-
tions of entorhinal slices from superficial
layer II/III after stimulation of layer II
(Fig. 1A,B). Regarding laminar differenti-
ation, superficial layers (I–III) receive pro-
jections from unimodal and polymodal
association areas via the perirhinal cortex
and then provide the majority of input
projections to the hippocampus (Witter et
al., 1989). Intrinsic associational fibers
originating from superficial layers are
confined within the same layers (Dolorfo
and Amaral, 1998). Previous studies have
shown that in different layers, including
superficial layer II/III of the entorhinal
cortex, LTP can be elicited (Alonso et al.,
1990; Yun et al., 2000) using various stim-
ulus patterns (Yun et al., 2002).
LTP was reliably elicited after HFS in
layer II. The mean LTP was 133% (SEM,
6%) of baseline amplitude at 50 min after
HFS (n  11 slices, 6 mice) (Fig. 1C).
When A42 at 200 nM (a concentration
shown to not cause cell death; see results in
cell culture below) was applied for 10 min,
starting 5 min before HFS delivery, in in-
terleaved experiments, LTP expression
was completely inhibited (98  6%, n  6, 4 mice; p  0.05) (Fig.
1C). A lower concentration of A42 (20 nM) did not affect LTP
(143  11%; n  6, 3 mice) (Fig. 1D). LTP amplitude was not
affected in slices treated with the reversed peptide A(42–1) (200
nM; 134  14%; n  8, 4 mice) (Fig. 1D). Impairment of synaptic
transmission by A42 was evaluated by measuring the amplitude
of FPs as a function of stimulus intensity. A42 did not change
the input– output curve with respect to vehicle-treated slices (Fig.
1E). The latter result, together with absence of baseline modifi-
cations by A42 (Fig. 1C), suggests that synaptic transmission is
not impaired by A42 in accordance with previous reports in
hippocampal slices (Chen et al., 2002; Vitolo et al., 2002; Ray-
Figure 1. Inhibitory effect of A42 on LTP in entorhinal cortex slices. A, Schematic drawing of entorhinal cortex slices and
position of electrodes (stimulus position in layer II, recording pipette in layer II/III). MEC, Medial entorhinal cortex; LEC, lateral
entorhinal cortex; DG, dentate gyrus; SUB, subiculum. B, Representative field potentials recorded before and 50 min after HFS in
vehicle-treated slices and in slices treated with A42 (200 nM). Calibration: 1 mV, 5 ms. Under control conditions LTP expression
is induced by HFS, applied after 15 min of baseline recording. C, LTP was induced by HFS stimulation in vehicle-treated slices (open
circles), whereas LTP expression was blocked by bath application of A42 (200 nM, gray circles) for 10 min (dark bar). D, No effect
on LTP expression was observed in the presence of reversed peptide A (42–1, 200 nM, open squares) or a low concentration of
A42 (20 nM, filled squares). E, Input– output curves. The relative amplitude (Rel. Amp.) as a function of stimulus intensity (Stim.
Int.) measured in volts (V) did not show significant differences between vehicle-treated (open circles) and A42-treated slices
(gray circles). F, Paired-pulse facilitation. Paired-pulse-induced change was calculated as the ratio of the peak amplitude of the
second evoked field potential to the first one (PP ratio) for different interstimulus intervals (25–200 ms). PP ratio was not modified
in A42 (200 nM, gray circles) treated slices respect to vehicle-treated slices (open circles). Error bars indicate SEM.
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mond et al., 2003; Wang et al., 2004). Fi-
nally, effects of A42 on short-term plas-
ticity were assayed using two consecutive
electrical stimuli (PP) applied at different
interstimulus intervals (30 –200 ms). The
PP ratio was unaffected by A42 (Fig. 1F).
Therefore, there was no indication that
A42 (200 nM) affects mechanisms of PP
facilitation.
RAGE deficiency rescues A42-induced
inhibition of LTP in the
entorhinal cortex
RAGE is a key cofactor mediating A-
induced synaptic plasticity impairment in
the hippocampus (Arancio et al., 2004).
To test whether RAGE was involved in
A42 entorhinal cortex impairment of
LTP, we examined the effect of a brief ap-
plication of A42 on LTP in cortical slices
from RAGE-null mice and in slices from
WT mice pretreated with anti-RAGE IgG.
Input– output curves (Fig. 2A, left), as
well as short-term plasticity properties
(PP ratio) (Fig. 2A, right), did not differ
between RAGE-null slices and anti-RAGE
IgG-treated slices from WT mice. The lat-
ter two demonstrated the same results as
cortical slices from age-matched WT mice
exposed to vehicle alone. Moreover, defi-
ciency of RAGE (RAGE-null mice) and
blockade of RAGE by specific antibodies
to the receptor (WT slices incubated with
anti-RAGE IgG, 2.5 g/ml for at least 2 h
before recordings) did not affect LTP (Fig.
2B). The mean LTP amplitude in RAGE-
null mice (135  11%; n  8, 4 mice) and
in slices from WT mice treated with anti-
RAGE IgG (131  6%; n  5, 3 mice) was
not significantly different with respect to
vehicle-treated WT slices, suggesting that
blockade of RAGE does not affect LTP in
entorhinal cortex. Remarkably, when
A42 (200 nM) was bath applied to RAGE-
null and anti-RAGE IgG-treated WT
slices, LTP was normal (Fig. 2C). The
mean LTP amplitude measured in RAGE-
null (126  2%; n  8, 5 mice) and anti-
RAGE IgG-incubated (136  7%; n  6, 4 mice) WT slices
treated with A42 was significantly increased ( p  0.05) with
respect to LTP in slices treated with A42 alone (control) (Fig.
2C). In contrast, values of LTP amplitude were similar in RAGE-
null slices or anti-RAGE IgG-treated WT slices without A.
Because RAGE is expressed in neurons as well as in other cells
(glial cells, endothelial cells) (Schmidt et al., 2001; Lue et al.,
2005), we determined whether neuronal RAGE is responsible for
A effects on LTP in entorhinal cortex. We investigated trans-
genic mice with signal transduction deficient mutants of RAGE in
which the cytosolic domain of the receptor has been deleted,
thereby imparting a dominant-negative phenotype, targeted to
neurons (DN-RAGE) by the PDGF-B chain promoter. The
PDGF-B chain promoter has been successfully used to drive ex-
pression of transgene targeted to neurons (Sasahara et al., 1991;
Mucke et al., 2000; Lustbader et al., 2004; Takuma et al., 2005).
Furthermore, transgenic mice expressing neuronal DN-RAGE
driven by the PDGF-B chain promoter have been previously
characterized, demonstrating localization of DN-RAGE in corti-
cal neurons (Arancio et al., 2004). Previous studies revealed that
these transgenic mice displayed preservation of spatial learning
and memory and decreased neuropathological changes when
bred into transgenic mice expressing mutant APP (Arancio et al.,
2004). Similar to what was observed in slices from RAGE-null
mice, LTP was unaffected in slices from transgenic mice with
defective RAGE targeted to neurons (DN-RAGE slices: 136 
10%, n  9, 5 mice; not significantly different from vehicle-
treated WT slices) (Fig. 2D). Most importantly, defective RAGE
signaling targeted to neurons protected against A-mediated re-
duction of LTP (DN-RAGE) (Fig. 2E); LTP values in DN-RAGE
Figure 2. Blockade of RAGE protects against A42 (200 nM)-induced reduction of LTP in entorhinal cortex slices. A, Left,
Input– output curves did not show significant differences between vehicle-treated WT slices (open circles) and RAGE-null slices
(filled circles) or WT slices treated with anti-RAGE IgG (open triangles). Right, Paired-pulse facilitation, PP ratio was not modified
in RAGE-null slices and in slices from WT mice treated with anti-RAGE IgG with respect to vehicle-treated slices. B, LTP expression
was unaffected in slices from RAGE-null mice (open circles) or in slices from WT mice preincubated with anti-RAGE IgG (2.5 g/ml
for 2 h, filled triangles) with respect to vehicle-treated slices (open circles). C, Left, Bath application (dark bar) of A42 (200 nM) did
not inhibit LTP in slices from RAGE-null mice (filled circles) or in slices from WT mice preincubated with anti-RAGE IgG (2.5 g/ml
for 2 h, open triangles) with respect to vehicle-treated slices (gray circles). Right, Representative field potentials recorded before
and 50 min after HFS in RAGE-null and anti-RAGE IgG-treated slices from WT mice; bath application of A was unable to block LTP.
Calibration: 1 mV, 5 ms. D, LTP expression was comparable in vehicle-treated slices from WT mice (open circles) and in slices from
Tg DN-RAGE (gray circles). E, A42 (200 nM, bath applied, dark bar) failed to inhibit LTP in DN-RAGE slices (gray circles). Error bars
indicate SEM.
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slices (127  5%; n  8, 5 mice) in the presence of A42 (200 nM)
were significantly increased ( p  0.05) with respect to slices from
WT mice treated with 200 nM A. Thus, functionless RAGE in
neurons was able to abolish A inhibition of LTP.
Based on a previous observations in double knock-in mice
carrying human mutations in the genes for APP and presenilin-1
showing that LTD was impaired, in addition to LTP (Chang et al.,
2006; but see Wang et al., 2002, showing no effect of exogenous
synthetic A42 on hippocampal LTD), we conducted a comple-
mentary study on the effects of A42 on LTD in entorhinal cortex
slices. LTD was reliably induced using paired-pulse LFS in agree-
ment with the report by Kourrich and Chapman (2003). After
this induction protocol, LTD magnitude was 84  5% (n  10
slices, 4 mice) (Fig. 3A). Consistent with data obtained by Wang
et al. (2002) in hippocampus, A42 (200 nM) did not affect LTD
in entorhinal cortex (77  10%; n  9 slices, 4 mice) (Fig. 3A)
( p  0.05 vs control vehicle-treated slices). Moreover, when we
tested LTD in RAGE-null slices, we found LTD to be normal (Fig.
3B) indicating that RAGE deficiency does not affect LTD expres-
sion in entorhinal cortex. Thus, LTD induced by LFS is not im-
paired by A42-RAGE signaling.
A42 impairment of LTP is prevented by inhibition of p38
MAPK but not JNK
Stress-related protein kinases, such as JNK and p38 MAPK, are
activated in several pathologic processes, including AD neurode-
generation and A42 cytotoxicity (Pei et al., 2001; Troy et al.,
2001; Zhu et al., 2005). It is noteworthy that both JNK and p38
MAPK inhibition prevented A-induced LTP impairment in
hippocampal slices (Wang et al., 2004). These observations sug-
gested the hypothesis that RAGE/A interaction induced impair-
ment of LTP through activation of specific kinase signaling cas-
cades. To evaluate this hypothesis, we tested the effect of MAPK
inhibitors on development of LTP in cortical slices. In particular,
we used a JNK inhibitor (SP600125) and a p38 MAPK inhibitor
(SB203580). SB203580 is a cell permeable inhibitor of p38 MAPK
(IC50, 0.3 M) showing a high selectivity at concentrations 2 M
(Lali et al., 2000). SP600125 is a potent selective and reversible
JNK inhibitor (IC50, 0.19 M) (Bennett et al., 2001). Perfusion
with either compound did not induce significant change in FP
amplitude during baseline recordings in entorhinal cortex slices
(Fig. 4A). When entorhinal cortex slices were continuously per-
fused with ACSF containing SB203580 (1 M) and SP600125 (20
M), LTP was normally expressed after HFS stimulation (131 
10%, n  6, 4 mice, and 146  11%, n  6, 4 mice, respectively;
not significantly different with respect to control LTP in vehicle-
treated slices) (Fig. 4A). Perfusion of the p38 inhibitor
(SB203580, 1 M) in the presence of A42 (200 nM, for 10 min
starting from 5 min before HFS delivery) restored normal LTP
(136  13%; n  7, 4 mice; p  0.05 vs A42 alone) (Fig. 4B).
LTP amplitude was not significantly different between
SB203580-treated and vehicle-treated slices ( p  0.05). In con-
trast, a specific inhibitor of JNK (SP600125, 20 M) failed to
rescue LTP in A42-treated slices (95  3%; n  6, 3 mice) (Fig.
4B). Input– output curves (Fig. 4C), as well as short-term plastic-
ity properties (PP ratio) (Fig. 4D), did not differ between
SB203580- (1 M) or SP600125 (20 M)-treated slices and age-
matched vehicle-treated WT slices.
A42 increases p38 MAPK phosphorylation in
cultured neurons
To further investigate the effect of RAGE-dependent activation of
p38 MAPK on A-mediated neuronal dysfunction, we measured
levels of p38 MAPK in primary cortical cultures. p38 MAPK is
activated by a variety of extracellular stimuli, including A pep-
tides, and is modulated by several upstream MAPK kinases
(MKK3, MKK4, MKK6), which phosphorylate p38 at threonine
180 and tyrosine 182 in the TGY motif (Ono and Han, 2000).
Phospho-p38[pTpY180/182] was measured in primary cultures
of mouse cortical neurons after exposure to A42 after different
incubation times and a range of concentrations. The kinetic pro-
file of p38 activation under these conditions (A42, 200 nM)
demonstrated an apparent maximum level of phosphorylation
after 10 min. Increasing incubation time to 1 h did not produce
any additional change in phospho-p38 (Fig. 5A). When neurons
were incubated with different concentrations of A42 for 10 min
(2 nM–20 M), we found a significant increase in phospho-p38
starting from a concentration of 200 nM, compared with vehicle-
treated control cultures (88  12.7 vs 28.1  18.7 U/ng total p38;
p  0.001) (Fig. 5B,C). Additional increases in A42 (2 and 20
M) did not induce significantly higher phosphorylation of p38
(Fig. 5B). Low concentrations of A (2 and 20 nM) did not pro-
duce any increase in phospho-p38 (Fig. 5B). Thus, A is able to
activate p38 MAPK at a concentration and with application times
in culture comparable with conditions in LTP experiments.
To determine the effect of RAGE on activation of p38 induced
by A, we have performed experiments with blocking anti-RAGE
antibodies in cell culture. When cells were pretreated with anti-
RAGE IgG (2.5 g/ml) for 2 h before exposure to A, levels of
phosho-p38 were significantly reduced compared with neurons
incubated with A alone (44.3  7.4 vs 88  12.7 U/ng total p38;
p  0.05, Fig. 5C). However, when anti-RAGE IgG was replaced
by nonimmune IgG (control, rabbit IgG), levels of phospho-p38
in A-treated cells were not decreased and remained significantly
higher in comparison with those of vehicle-treated control cells
Figure 3. LTD is not affected in entorhinal cortex slices treated with A42. A, LTD was
reliably inducible by LFS (arrow) in vehicle-treated slices (open circles) and A42-treated slices
from WT mice (A42, 200 nM; gray circles). The top horizontal dark bar corresponds to bath
applied A42. B, LTD was unimpaired in slices from RAGE-null mice. Error bars indicate SEM.
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(91.9  13 vs 28  18.7 U/ng total p38, Fig. 5C).
These results suggest that blocking RAGE by ad-
ministration of anti-RAGE IgG suppressed A-
mediated activation of p38. Furthermore, we
used hydrogen peroxide (H2O2) in the incuba-
tion medium (10 min at 100 M) to activate p38
to estimate maximal levels of phospho-p38 and
to examine whether H2O2-induced activation of
p38 might also be mediated by RAGE. Under the
latter conditions (dose and time of exposure to
H2O2), cultured cortical neurons displayed acti-
vation of p38 MAPK in the absence of cytotoxic-
ity (Wang et al., 2003). Indeed, we found that
H2O2 significantly increased phospho-p38 with
respect to control cultures (110  20.2 U/ng total
p38, p  0.001 vs vehicle-treated cultures; p 
0.3 vs A-treated cultures) (Fig. 5C). Impor-
tantly, anti-RAGE IgG did not block increased
levels of phospho-p38 induced by H2O2 (118.6 
5.4 vs 110  20.2 in cultures incubated with
H2O2, Fig. 5C). Administration of nonimmune
IgG alone did not affect baseline levels of
phospho-p38 (Fig. 5C). These results further
support the concept that A-mediated activa-
tion of p38 MAPK occurred as a downstream
consequence of RAGE-A interaction.
In additional experiments, we assessed
whether A42 (200 nM) induced cell death using
two different methods: 1 h incubation with PI
and a biochemical assay measuring LDH activity
(supplemental Fig. 1, available at www.jneuro-
sci.org as supplemental material). No evidence of
cell death was observed with 200 nM A42 using
either of these methods. In addition, immunocy-
tochemical analysis with an antibody to the acti-
vated form of caspase-3 (a marker of apoptosis)
showed that A42 (200 nM) did not significantly
increase the number of apoptotic cells even with
prolonged A incubation (supplemental Fig. 2,
available at www.jneurosci.org as supplemental material).
Together, these results obtained with cultured neurons re-
vealed that (1) A is able to activate p38 MAPK when applied at
nM concentrations, and (2) the increase in phospho-p38 can be
prevented by blocking RAGE. Furthermore, it is plausible that
RAGE-mediated activation of p38 MAPK in neurons after expo-
sure to A42 might represent a cellular mechanism accounting
for LTP impairment.
Discussion
Oligomeric forms of A play a critical role in the pathogenesis of
AD. In particular, A is believed to contribute to early impair-
ment of cognitive functions such as learning and memory (Cleary
et al., 2005; Lesne et al., 2006). Such early signs of functional
impairment precede extensive neurodegeneration characteristic
of the middle/late phase of AD, which includes extensive deposi-
tion of amyloid in the form of plaques. Although not completely
clear, the mechanism underlying early functional impairment is
likely to involve perturbation of synapse efficacy in different
brain areas in the presence of an environment with increased
extracellular levels of A. Consistent with this hypothesis, oligo-
meric A affects long-term forms of synaptic plasticity, such as
LTP in the hippocampus (Lambert et al., 1998; Chen et al., 2002;
Vitolo et al., 2002; Wang et al., 2004; Puzzo et al., 2005), a brain
area fundamentally involved in learning and memory. We have
focused our work on entorhinal cortex slices, because this region
is a major locus of information exchange between the hippocam-
pus and other cortical areas (Witter et al., 1989; Braak and Braak,
1993; Suzuki and Amaral, 2004) that is also affected at an early
stage of AD (Braak and Braak, 1991). In addition, synaptic trans-
mission and long-term synaptic plasticity in the forms of LTP and
LTD are well characterized in the entorhinal cortex layers
(Alonso et al., 1990; Yun et al., 2000, 2002; Kourrich and Chap-
man, 2003) representing a suitable assay to probe neuronal
function.
Our experiments indicate that oligomeric A42, at a concen-
tration of 200 nM, is capable of blocking LTP, but not LTD or PP,
at cortical synapses in the entorhinal cortex. The present results
in the entorhinal cortex confirm previous data obtained in hip-
pocampus, which showed that oligomeric A impairs LTP
(Walsh et al., 2002, 2005; Wang et al., 2004). Also, our results are
in agreement with Wang et al. (2002), who showed that soluble
A inhibited LTP in the hippocampus without affecting LTD.
Thus, it is likely that even brief exposure to 200 nM A42 specif-
ically perturbs LTP in the entorhinal cortex. In contrast, A42 at
the same concentration did not induce a concomitant impair-
ment of synaptic transmission as evaluated by input– output
functions and baseline neurotransmission. A few reports have
Figure 4. A42 impairment of LTP is prevented by inhibition of p38 MAPK, but not JNK in entorhinal cortex slices
from WT mice. A, LTP induction and maintenance was not affected by continuous perfusion with 1 M SB203580 (p38
MAPK inhibitor) (filled square) or 20 M SP600125 (JNK inhibitor) (gray diamonds). Top, Representative field potentials
recorded before and 50 min after HFS slices treated with SB203580. B, SB203580 (1 M), but not SP600125 (20 M),
perfusion prevented LTP blockade in A42-treated slices (bath application at 200 nM corresponding to dark bar). Top,
Representative field potentials recorded before and 50 min after HFS in slices treated with SB203580 and A42. Cali-
bration: A, B, 1 mV, 5 ms. C, Input– output curves. Slice perfusion with ACSF containing 1 M SB203580 (filled squares)
or 20 M SP600125 (open triangles) did not change the input– output curves with respect to vehicle-treated slices (open
circles). D, Paired-pulse facilitation, PP ratio was not modified in 1 M SB203580- and 20 M SP600125-treated slices
with respect to vehicle-treated slices; other conventions are as in C. Error bars indicate SEM.
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shown that administration of A at low M concentrations (i.e.,
at concentrations higher than that used in the present work) can
depress synaptic transmission by regulating glutamate receptors
trafficking (Snyder et al., 2005; Tyszkiewicz and Yan, 2005; Hsieh
et al., 2006; Parameshwaran et al., 2007). Moreover, higher levels
of A, thought to be present in intermediate/late stages of neu-
rodegeneration, may affect synaptic transmission and LTD in
addition to LTP by regulating trafficking of AMPA- and/or
NMDA-receptors (Hsia et al., 1999; Oddo et al., 2003; Chang et
al., 2006; Shemer et al., 2006). Interestingly, studies conducted in
animal models of AD characterized by progressive accumulation
of A42 have shown that LTP disruption occurs before deficits in
basal transmission (Trinchese et al., 2004; Chang et al., 2006) and
LTD (Chang et al., 2006). Thus, these results in animal models of
AD and synthetic A lend support to the concept that impaired
LTP characterizes an early stage in AD progression correspond-
ing to a low A load. Later stages in AD progression are associated
with a greater A load and also affect basal synaptic transmission
and LTD.
Concerning the possible cell surface receptors that are able to
bind A and activate downstream intracellular cascades leading
to LTP impairment, a number of studies have identified RAGE as
a receptor capable of binding to A, in monomeric, fibrillized,
and oligomeric form (for review, see Ding and Keller, 2005) (S. D.
Yan, unpublished observation) at the cell
surface (Lue et al., 2001). RAGE immuno-
reactivity is present at sites of A deposi-
tion and binding of A is considered an
important event, increasing A aggrega-
tion at the cell membrane (Yan et al., 1996,
1998). This viewpoint assigns an impor-
tant role for A engagement of RAGE in
downstream signaling and effector mech-
anisms leading to oxidative stress, inflam-
mation, and neurotoxicity. Moreover,
RAGE has been implicated as an impor-
tant cofactor for A-induced neuronal
dysfunction in a murine model of AD (Tg
APP mice). Indeed, hippocampal LTP was
altered only in double-Tg mice (express-
ing RAGE/mutant APP transgenes) and
not in single Tg mice (mutant APP or
RAGE), suggesting that overexpression of
RAGE in an A-rich environment per-
turbs synaptic efficacy (Arancio et al.,
2004). In the present study, we found that
RAGE deficiency or functional blockade
of RAGE by specific antibodies counter-
acts LTP dysfunction induced by A42.
Because RAGE is expressed in neurons, as
well as other cells critical for neurodegen-
erative pathology (glial cells, endothelial
cells and pericytes of the blood– brain bar-
rier) (Schmidt et al., 2001; Lue et al.,
2005), we sought to determine whether
neuronal RAGE was responsible for A-
dependent LTP impairment in entorhinal
cortex. To shed light on this issue, we
made use of transgenic mice with a signal
transduction deficient mutant of RAGE in
which the cytosolic domain of the receptor
had been deleted, thereby imparting a
DN-RAGE effect. The latter transgene was
targeted to neurons (DN-RAGE) by the PDGF-B chain pro-
moter. Previous data reported that expression of DN-RAGE,
even in cells expressing wild-type RAGE, blocked RAGE-
dependent cellular activation (Hofmann et al., 1999; Arancio et
al., 2004). Our findings clearly showed that entorhinal cortex
slices from DN-RAGE transgenic mice were resistant to disrup-
tion of LTP by 200 nM A, suggesting the involvement of neuro-
nal RAGE in mechanisms leading to A-induced cortical inhibi-
tion of LTP. Our results do not exclude that non-neuronal RAGE
(RAGE expressed in glial cells, endothelial cells and pericytes of
the blood– brain barrier) might be involved in synaptic dysfunc-
tion associated with oxidative stress, inflammation, and neuro-
toxicity characterizing AD progression, as suggested by a previ-
ous study (Lue et al., 2001). In perspective, it will be interesting to
investigate the role of non-neuronal RAGE in synaptic failure
induced by A.
Signaling cascades activated after ligand–RAGE interaction
include pathways such as p21ras, extracellular signal-regulated
kinase 1/2 (p44/p42) MAP kinases, p38 MAPK and SAPK (stress-
activated protein kinase)/JNK, Rho GTPases, phosphoinositol-3
kinase, and the JAK/STAT (signal transducer and activator of
transcription) pathway. Downstream consequences, such as the
activation of the key transcription factors, nuclear factor-B and
CREB (cAMP response element binding protein), have also been
Figure 5. p38 MAPK phosphorylation increased in cultured neurons exposed to a nontoxic concentration of A42. A, Effect of
A42 (200 nM) on p38 phosphorylation at different incubation times (n  6 experiments for each group; *p  0.05 vs control
untreated cells). B, Effect of increasing concentrations of A42 on p38 phosphorylation; 200 nM A42 significantly increased
phospho-p38 levels (n  6 experiments in each group, *p  0.001 vs control untreated). No additional increase was induced by
higher concentrations A42 (2 and 20 M). C, A42 (200 nM, 10 min incubation) or H2O2 (100 M, 10 min) increased p38
phosphorylation compared with anti-RAGE IgG. Levels of p38 phosphorylation in cultures exposed to A42 in the presence of
anti-RAGE IgG were similar to those observed in cultures not exposed to A42 and incubated with control IgG or in control cells
( #p  0.001). Anti-RAGE IgG pretreatment of neuronal cultures significantly reduced A-, but not H2O2-induced increase in
phospho-p38 (*p  0.05 vs A42 200 nM; n  6 experiments for each group). Error bars indicate SEM.
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reported previously (Lander et al., 1997; Deora et al., 1998; Hof-
mann et al., 1999; Huttunen et al., 1999; Kislinger et al., 1999;
Huang et al., 2001). Activation of different protein kinase cas-
cades is a principal target of RAGE activation in the pathway
controlling synaptic plasticity. In particular, we considered two
different kinases, namely JNK and p38 MAPK as potentially in-
volved in inhibition of LTP. Recent results showed that p38
MAPK and JNK activation are required for LTP inhibition in-
duced by proinflammatory agents such as interleukin-1 and
lipopolysaccharide (Curran et al., 2003; Kelly et al., 2003). These
results prompted us to test whether p38 MAPK and JNK were
involved in LTP inhibition by A. In contrast to inflammatory
stimuli, A induced LTP impairment could be prevented by a
p38 MAPK inhibitor alone, suggesting that activation of this
downstream kinase is a key event in the A-initiated signaling
pathway. Our results are in agreement with previous data ob-
tained in the RAGE/mutant APP double-transgenic mice that
showed a role for RAGE in the activation of p38 MAPK in the
hippocampus during AD-like neurodegeneration (Arancio et al.,
2004). Although, the role of p38 MAPK in the pathogenesis of AD
has been well established (Hensley et al., 1999; Zhu et al., 2005),
we also investigated the role of another major stress-activated
protein kinase, namely, JNK. However, inhibition of JNK with
SP600125 was ineffective in rescuing cortical LTP after treatment
of entorhinal cortex slices from WT mice with A. According to
the work of others, inhibition of JNK only partially rescued LTP
after the application of synthetic A42 peptide in the hippocam-
pus (Wang et al., 2004), leading us to conclude that A-induced
inhibition of LTP may occur via a proinflammatory pathway that
is principally controlled by activation of p38 MAPK. These ob-
servations are further supported by our results showing that
A42 at nontoxic concentrations was able to phosphorylate p38
MAPK in cultured cortical neurons. In contrast, addition of anti-
RAGE IgG to neuronal cultures prevented A42-mediated acti-
vation of p38 MAPK. However, delineation of the precise route
from p38 MAPK phosphorylation to the key substrate(s) leading
to A-dependent LTP impairment has yet to be identified.
Together, our results indicate that neuronal RAGE is involved
in mechanisms underlying A-induced inhibition of LTP, at least
in part, through activation of p38 MAPK in mouse cortex. This
work contributes to an increasing body of evidence that activa-
tion of RAGE by oligomeric A represents an important early
step in neuronal dysfunction before amyloid plaque deposition.
Thus, RAGE activation by A may lead to an early impairment of
cognitive functions in brain areas critically affected in AD.
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